829 reports of this reaction
1.6% of all DEFERASIROX reports
#14 most reported adverse reaction
BLOOD CREATININE INCREASED is the #14 most commonly reported adverse reaction for DEFERASIROX, manufactured by Novartis Pharmaceuticals Corporation. There are 829 FDA adverse event reports linking DEFERASIROX to BLOOD CREATININE INCREASED. This represents approximately 1.6% of all 50,952 adverse event reports for this drug.
Patients taking DEFERASIROX who experience blood creatinine increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD CREATININE INCREASED is a less commonly reported adverse event for DEFERASIROX, but still significant enough to appear in the safety profile.
In addition to blood creatinine increased, the following adverse reactions have been reported for DEFERASIROX:
The following drugs have also been linked to blood creatinine increased in FDA adverse event reports:
BLOOD CREATININE INCREASED has been reported as an adverse event in 829 FDA reports for DEFERASIROX. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD CREATININE INCREASED accounts for approximately 1.6% of all adverse event reports for DEFERASIROX, making it a notable side effect.
If you experience blood creatinine increased while taking DEFERASIROX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.